Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Table 1

Baseline clinical characteristics of the intervention and control groups before resveratrol or placebo supplementation.

	Control group	Intervention group	P value
Age (yrs)	51.81±6.99	52.45±6.18	0.697
Sex (female/male)	16/17	17/16	0.806
Duration of disease (yrs)	5.39±1.36	5.81±1.53	0.239
Family history of diabetes (yrs)	24 (77.4%)	15 (50.0%)	0.024*
Smoking (n)	4 (12.9%)	7 (21.90%)	0.348
History of hypertension (n)	8 (27.6%)	9 (29.0%)	0.901

Data is presented as means ± SD. For history of diabetes, smoking, and hypertension, the bracketed value corresponds to the total percentage of participants in respective groups. ^∗𝑃<0.05 versus control group.